Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naprosyn 500 mg Clear all
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 6, 2026, 1:54 PM EDT
Not listed Not applicable Interventional

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

NCT01557816
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Naproxen, Placebo
Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Francisco, California • Kalamazoo, Michigan • Springfield, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

Are Opioids Needed After ACL Reconstruction

NCT04285853
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Oxycodone, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
14 Years to 40 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

NCT00504127
View directory record Official record
Conditions
Osteoarthritis
Interventions
Naproxcinod 375 mg bid, Naproxcinod 750 mg bid, Naproxen 500 mg bid, placebo
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
73
States / cities
Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 6, 2026, 1:54 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Variability in Response to Non-steroidal Anti-inflammatory Drugs

NCT02502006
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Naproxen, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

NCT00969449
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Naproxen Sodium, (BAY H6689), Naprelan, (BAY H6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

NCT00665743
View directory record Official record
Conditions
Arthritis
Interventions
PN400, naproxen
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT00807846
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

NCT03448536
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Naproxen Sodium, (Aleve, BAY117031), Acetaminophen (Tylenol Extra Strength)
Drug
Lead sponsor
Bayer
Industry
Eligibility
15 Years to 35 Years · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Chandler, Arizona • Scottsdale, Arizona • Pinellas Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
View directory record Official record
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 6, 2026, 1:54 PM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 6, 2026, 1:54 PM EDT
Terminated Phase 4 Interventional Results available

Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery

NCT04990804
View directory record Official record
Conditions
Opioid Use, Spinal Diseases, Surgery--Complications, Surgery, Postoperative Pain
Interventions
Opioid Analgesic, Opioid-Free Postoperative Pain Regimen
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Results available

Ketamine for Acute Pain Management After Trauma

NCT04129086
View directory record Official record
Conditions
Trauma Injury, Pain, Opioid Use
Interventions
Ketamine plus usual care, Usual Care
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 6, 2026, 1:54 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

NCT00966641
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Naproxen, PL 3100
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 6, 2026, 1:54 PM EDT
Recruiting No phase listed Observational

CHronic Nonbacterial Osteomyelitis International Registry

NCT04725422
View directory record Official record
Conditions
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 6, 2026, 1:54 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

NCT07750639
View directory record Official record
Conditions
Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions
Naproxen, Acetaminophen, oxycodone, Gabapentin
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

NCT03879408
View directory record Official record
Conditions
Pain
Interventions
440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 6, 2026, 1:54 PM EDT
Completed Phase 2Phase 3 Interventional

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

NCT01063920
View directory record Official record
Conditions
Osteoarthritis
Interventions
LT-NS001, Naprosyn®
Drug
Lead sponsor
Logical Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Sep 6, 2026, 1:54 PM EDT
Terminated Phase 4 Interventional Results available

Dronabinol On the Pain Experience

NCT05820685
View directory record Official record
Conditions
Trauma Injury
Interventions
Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol), Dronabinol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years to 80 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 6, 2026, 1:54 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Phenotyping Acute Pain for Discovery Research and Directed Therapeutics

NCT02322996
View directory record Official record
Conditions
Post op Pain
Interventions
questionnaires
Other
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 6, 2026, 1:54 PM EDT